231 related articles for article (PubMed ID: 22736175)
21. [Regulation of matrix-degrading enzymes in gynecologic cancer tissues and cells].
Kikkawa F
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):618-22. PubMed ID: 8808829
[TBL] [Abstract][Full Text] [Related]
22. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
Kim JR; Kim CH
Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
[TBL] [Abstract][Full Text] [Related]
23. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.
Figueira RC; Gomes LR; Neto JS; Silva FC; Silva ID; Sogayar MC
BMC Cancer; 2009 Jan; 9():20. PubMed ID: 19144199
[TBL] [Abstract][Full Text] [Related]
24. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
Kim IS; Yang WS; Kim CH
Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases and their inhibitors regulate in vitro ureteric bud branching morphogenesis.
Pohl M; Sakurai H; Bush KT; Nigam SK
Am J Physiol Renal Physiol; 2000 Nov; 279(5):F891-900. PubMed ID: 11053050
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase (MMP) induction and inhibition at different doses of recombinant tissue plasminogen activator following experimental stroke.
Burggraf D; Martens HK; Dichgans M; Hamann GF
Thromb Haemost; 2007 Nov; 98(5):963-9. PubMed ID: 18000599
[TBL] [Abstract][Full Text] [Related]
27. [Matrix metalloproteinases (MMP)--MMP-1,-2,-9 and its endogenous activity regulators in transformed by E7 oncogene HPV16 and HPV18 cervical carcinoma cell lines].
Ryzhakova OS; Solov'eva NI
Biomed Khim; 2013; 59(5):530-40. PubMed ID: 24479343
[TBL] [Abstract][Full Text] [Related]
28. Secretion of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases into the intrauterine compartments during early pregnancy.
Riley SC; Leask R; Chard T; Wathen NC; Calder AA; Howe DC
Mol Hum Reprod; 1999 Apr; 5(4):376-81. PubMed ID: 10321811
[TBL] [Abstract][Full Text] [Related]
29. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
González-Cuevas J; Bueno-Topete M; Armendariz-Borunda J
J Gastroenterol Hepatol; 2006 Oct; 21(10):1544-54. PubMed ID: 16928215
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinases and their tissue inhibitors in the developing neonatal mouse uterus.
Hu J; Zhang X; Nothnick WB; Spencer TE
Biol Reprod; 2004 Nov; 71(5):1598-604. PubMed ID: 15240428
[TBL] [Abstract][Full Text] [Related]
31. Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines.
Liu Z; Ivanoff A; Klominek J
Int J Cancer; 2001 Mar; 91(5):638-43. PubMed ID: 11267973
[TBL] [Abstract][Full Text] [Related]
32. Allyl isothiocyanate and its N-acetylcysteine conjugate suppress metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in SK-Hep 1 human hepatoma cells.
Hwang ES; Lee HJ
Exp Biol Med (Maywood); 2006 Apr; 231(4):421-30. PubMed ID: 16565438
[TBL] [Abstract][Full Text] [Related]
33. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
34. Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Hsieh YS; Yang SF; Lue KH; Chu SC; Lu KH
J Orthop Res; 2008 Apr; 26(4):475-84. PubMed ID: 17975844
[TBL] [Abstract][Full Text] [Related]
35. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
de Bart AC; Quax PH; Löwik CW; Verheijen JH
J Bone Miner Res; 1995 Sep; 10(9):1374-84. PubMed ID: 7502710
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.
Zhang X; Sakamoto T; Hata Y; Kubota T; Hisatomi T; Murata T; Ishibashi T; Inomata H
Exp Eye Res; 2002 May; 74(5):577-84. PubMed ID: 12076079
[TBL] [Abstract][Full Text] [Related]
37. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases.
Sato T; Sakai T; Noguchi Y; Takita M; Hirakawa S; Ito A
Gynecol Oncol; 2004 Jan; 92(1):47-56. PubMed ID: 14751137
[TBL] [Abstract][Full Text] [Related]
38. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
Emenaker NJ; Basson MD
J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
[TBL] [Abstract][Full Text] [Related]
39. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
40. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
Chu SC; Chiou HL; Chen PN; Yang SF; Hsieh YS
Mol Carcinog; 2004 Jul; 40(3):143-9. PubMed ID: 15224346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
